Contact
Talk to us through the assistant
Most questions - patient, clinician, investor, or media - are answered immediately by the assistant on this site, within our published guardrails. For trial-specific contact, the named site investigator is listed below.
Ask the assistant
The fastest way to reach us. The assistant answers questions about CCI-001, the PMH-001 Phase 1 trial, eligibility prep, our team, the May 21 publication, and how investors or media can engage.
You can open the assistant from either the AI button in the top-right of the navigation bar or the chat button in the bottom-right corner of any page.
Trial contact (NCT04823897)
The named site contact for the PMH-001 Phase 1 trial is listed on ClinicalTrials.gov, alongside the principal investigator and study site phone number.
A few important notes
- The assistant is for information only. It is not medical advice and does not screen anyone for the trial - eligibility is decided only by the trial investigators after a screening visit.
- Please don't share detailed medical records, lab values, or images through the assistant. Save those for the formal screening visit.
- For media or investor inquiries that require non-public materials, the assistant will guide you through a CDA / NDA request.
- If your situation is urgent, contact your local emergency services or your treating physician.
Prefer a form? Send us a message
Use this form if you'd rather email the team directly. We'll route your inquiry to the right person — clinical, scientific, investor, media, or partnerships — and follow up by email.